Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H32O13 |
Molecular Weight | 588.5566 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=CC(OC)=C1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]4O)C6=C2C=C7OCOC7=C6
InChI
InChIKey=VJJPUSNTGOMMGY-MRVIYFEKSA-N
InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1
Molecular Formula | C29H32O13 |
Molecular Weight | 588.5566 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16101488Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020457s013lbl.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16101488
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020457s013lbl.pdf
Etoposide (trade name Etopophos) is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. It has been in clinical use for more than two decades and remains one of the most highly prescribed anticancer drugs in the world. The primary cytotoxic target for etoposide is topoisomerase II. This ubiquitous enzyme regulates DNA under- and over winding, and removes knots and tangles from the genome by generating transient double-stranded breaks in the double helix. Etoposide kills cells by stabilizing a covalent enzyme-cleaved DNA complex (known as the cleavage complex) that is a transient intermediate in the catalytic cycle of topoisomerase II. The accumulation of cleavage complexes in treated cells leads to the generation of permanent DNA strand breaks, which trigger recombination/repair pathways, mutagenesis, and chromosomal translocations. If these breaks overwhelm the cell, they can initiate death pathways. Thus, etoposide converts topoisomerase II from an essential enzyme to a potent cellular toxin that fragments the genome. Although the topoisomerase II-DNA cleavage complex is an important target for cancer chemotherapy, there also is evidence that topoisomerase II-mediated DNA strand breaks induced by etoposide and other agents can trigger chromosomal translocations that lead to specific types of leukemia. Etopophos (etoposide phosphate) is indicated in the management of the following neoplasms: Refractory Testicular Tumors-and for Small Cell Lung Cancer. The in vitro cytotoxicity observed for etoposide phosphate is significantly less than that seen with etoposide, which is believed due to the necessity for conversion in vivo to the active moiety, etoposide, by dephosphorylation. The mechanism of action is believed to be the same as that of etoposide.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16101488 |
0.8 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ETOPOPHOS PRESERVATIVE FREE Approved UseETOPOPHOS for Injection is indicated in the management of the following neoplasms: Refractory Testicular Tumors-ETOPOPHOS for Injection in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy. Small Cell Lung Cancer-ETOPOPHOS for Injection in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer. Launch Date1983 |
|||
Primary | ETOPOPHOS PRESERVATIVE FREE Approved UseETOPOPHOS for Injection is indicated in the management of the following neoplasms: Refractory Testicular Tumors-ETOPOPHOS for Injection in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy. Small Cell Lung Cancer-ETOPOPHOS for Injection in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer. Launch Date1996 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.7 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8431968 |
80 mg/m² other, intravenous dose: 80 mg/m² route of administration: Intravenous experiment type: OTHER co-administered: |
ETOPOSIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
18.66 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8431968 |
95 mg/m² other, intravenous dose: 95 mg/m² route of administration: Intravenous experiment type: OTHER co-administered: |
ETOPOSIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2707 μg × min/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8431968 |
80 mg/m² other, intravenous dose: 80 mg/m² route of administration: Intravenous experiment type: OTHER co-administered: |
ETOPOSIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5806 μg × min/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8431968 |
95 mg/m² other, intravenous dose: 95 mg/m² route of administration: Intravenous experiment type: OTHER co-administered: |
ETOPOSIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.37 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8431968 |
80 mg/m² other, intravenous dose: 80 mg/m² route of administration: Intravenous experiment type: OTHER co-administered: |
ETOPOSIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.32 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8431968 |
95 mg/m² other, intravenous dose: 95 mg/m² route of administration: Intravenous experiment type: OTHER co-administered: |
ETOPOSIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3% |
ETOPOSIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
25 mg/m2 3 times / day multiple, oral Highest studied dose Dose: 25 mg/m2, 3 times / day Route: oral Route: multiple Dose: 25 mg/m2, 3 times / day Sources: |
unhealthy, 1.1-17 |
DLT: Neutropenia, Thrombocytopenia... Dose limiting toxicities: Neutropenia (grade 4, 25%) Sources: Thrombocytopenia (grade 4, 12.5%) Leukopenia (grade 4, 12.5%) Diarrhea (grade 3, 12.5%) Diarrhea (grade 4, 12.5%) |
20 mg/m2 3 times / day multiple, oral MTD Dose: 20 mg/m2, 3 times / day Route: oral Route: multiple Dose: 20 mg/m2, 3 times / day Sources: |
unhealthy, 1.1-17 |
DLT: Neutropenia... |
175 mg/m2 1 times / day multiple, intravenous MTD Dose: 175 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 175 mg/m2, 1 times / day Sources: |
unhealthy, 39-72 |
DLT: Neutropenia... Dose limiting toxicities: Neutropenia (grade 4, 28.6%) Sources: |
175 mg/m2 1 times / day multiple, intravenous MTD Dose: 175 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 175 mg/m2, 1 times / day Sources: |
unhealthy, 39-72 |
DLT: Neutropenia... Dose limiting toxicities: Neutropenia (grade 3, 14.3%) Sources: |
220 mg/m2 1 times / day multiple, intravenous MTD Dose: 220 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / day Sources: |
unhealthy, 39-72 |
DLT: Neutropenia, Neutropenia... Dose limiting toxicities: Neutropenia (grade 3, 25%) Sources: Neutropenia (grade 4, 25%) |
60 mg/m2 1 times / day multiple, oral Recommended Dose: 60 mg/m2, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2, 1 times / day Sources: |
unhealthy, 39-83 |
DLT: Leukopenia, Neutropenia... Disc. AE: Nausea and vomiting, Fatigue... Dose limiting toxicities: Leukopenia (grade 4, 12%) AEs leading toNeutropenia (grade 4, 25%) Leukopenia (grade 3, 29%) Neutropenia (grade 3, 20%) Thrombocytopenia (grade 4, 4%) discontinuation/dose reduction: Nausea and vomiting (3%) Sources: Fatigue (1%) Neutropenic sepsis (grade 5, 2%) Bleeding (grade 5, 1%) |
100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Myelosuppression... AEs leading to discontinuation/dose reduction: Myelosuppression (severe) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Diarrhea | grade 3, 12.5% DLT |
25 mg/m2 3 times / day multiple, oral Highest studied dose Dose: 25 mg/m2, 3 times / day Route: oral Route: multiple Dose: 25 mg/m2, 3 times / day Sources: |
unhealthy, 1.1-17 |
Leukopenia | grade 4, 12.5% DLT |
25 mg/m2 3 times / day multiple, oral Highest studied dose Dose: 25 mg/m2, 3 times / day Route: oral Route: multiple Dose: 25 mg/m2, 3 times / day Sources: |
unhealthy, 1.1-17 |
Thrombocytopenia | grade 4, 12.5% DLT |
25 mg/m2 3 times / day multiple, oral Highest studied dose Dose: 25 mg/m2, 3 times / day Route: oral Route: multiple Dose: 25 mg/m2, 3 times / day Sources: |
unhealthy, 1.1-17 |
Diarrhea | grade 4, 12.5% DLT, Disc. AE |
25 mg/m2 3 times / day multiple, oral Highest studied dose Dose: 25 mg/m2, 3 times / day Route: oral Route: multiple Dose: 25 mg/m2, 3 times / day Sources: |
unhealthy, 1.1-17 |
Neutropenia | grade 4, 25% DLT |
25 mg/m2 3 times / day multiple, oral Highest studied dose Dose: 25 mg/m2, 3 times / day Route: oral Route: multiple Dose: 25 mg/m2, 3 times / day Sources: |
unhealthy, 1.1-17 |
Neutropenia | grade 4, 14% DLT |
20 mg/m2 3 times / day multiple, oral MTD Dose: 20 mg/m2, 3 times / day Route: oral Route: multiple Dose: 20 mg/m2, 3 times / day Sources: |
unhealthy, 1.1-17 |
Neutropenia | grade 4, 28.6% DLT |
175 mg/m2 1 times / day multiple, intravenous MTD Dose: 175 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 175 mg/m2, 1 times / day Sources: |
unhealthy, 39-72 |
Neutropenia | grade 3, 14.3% DLT |
175 mg/m2 1 times / day multiple, intravenous MTD Dose: 175 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 175 mg/m2, 1 times / day Sources: |
unhealthy, 39-72 |
Neutropenia | grade 3, 25% DLT |
220 mg/m2 1 times / day multiple, intravenous MTD Dose: 220 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / day Sources: |
unhealthy, 39-72 |
Neutropenia | grade 4, 25% DLT |
220 mg/m2 1 times / day multiple, intravenous MTD Dose: 220 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / day Sources: |
unhealthy, 39-72 |
Fatigue | 1% Disc. AE |
60 mg/m2 1 times / day multiple, oral Recommended Dose: 60 mg/m2, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2, 1 times / day Sources: |
unhealthy, 39-83 |
Nausea and vomiting | 3% Disc. AE |
60 mg/m2 1 times / day multiple, oral Recommended Dose: 60 mg/m2, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2, 1 times / day Sources: |
unhealthy, 39-83 |
Neutropenia | grade 3, 20% DLT |
60 mg/m2 1 times / day multiple, oral Recommended Dose: 60 mg/m2, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2, 1 times / day Sources: |
unhealthy, 39-83 |
Leukopenia | grade 3, 29% DLT |
60 mg/m2 1 times / day multiple, oral Recommended Dose: 60 mg/m2, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2, 1 times / day Sources: |
unhealthy, 39-83 |
Leukopenia | grade 4, 12% DLT |
60 mg/m2 1 times / day multiple, oral Recommended Dose: 60 mg/m2, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2, 1 times / day Sources: |
unhealthy, 39-83 |
Neutropenia | grade 4, 25% DLT |
60 mg/m2 1 times / day multiple, oral Recommended Dose: 60 mg/m2, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2, 1 times / day Sources: |
unhealthy, 39-83 |
Thrombocytopenia | grade 4, 4% DLT |
60 mg/m2 1 times / day multiple, oral Recommended Dose: 60 mg/m2, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2, 1 times / day Sources: |
unhealthy, 39-83 |
Bleeding | grade 5, 1% Disc. AE |
60 mg/m2 1 times / day multiple, oral Recommended Dose: 60 mg/m2, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2, 1 times / day Sources: |
unhealthy, 39-83 |
Neutropenic sepsis | grade 5, 2% Disc. AE |
60 mg/m2 1 times / day multiple, oral Recommended Dose: 60 mg/m2, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2, 1 times / day Sources: |
unhealthy, 39-83 |
Myelosuppression | severe Disc. AE |
100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/15319341/ |
slight | |||
weak [Ki 756 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | weak (co-administration study) Comment: Ketoconazole increased the area under the plasma concentration-time curve (AUC) of oral etoposide by a median of 20% |
|||
major | yes (pharmacogenomic study) Comment: UGT1A1*28 and UGT1A1*6 mutations might be regarded as predictors for etoposide-induced grade 4 neutropenia. Sources: https://pubmed.ncbi.nlm.nih.gov/17151191/ |
|||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Etoposide-induced hypersensitivity reactions. Report of two cases. | 1985 Dec |
|
Expression of p21 and bcl-2 proteins and p53 mRNA in surgically resected preparations of non-small cell lung cancer (stage IIIA) after etoposide and cisplatin chemotherapy. | 2001 |
|
High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer. | 2001 Apr |
|
Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. | 2001 Feb |
|
Transcriptional activation of short interspersed elements by DNA-damaging agents. | 2001 Jan |
|
High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results. | 2001 May |
|
Irinotecan: future directions in small-cell lung cancer. | 2001 May |
|
Langerhans cell histiocytosis. | 2001 Nov |
|
Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase. | 2001 Nov 1 |
|
The importance of drug scheduling and recovery phases in determining drug activity. Improving etoposide efficacy in BCR-ABL-positive CML cells. | 2002 Apr |
|
Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. | 2002 Nov 22 |
|
Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. | 2002 Sep 26 |
|
High-dose chemotherapy and autologous peripheral blood stem cell rescue in a patient with pleuropulmonary blastoma. | 2003 Jan |
|
Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. | 2003 Sep 1 |
|
Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer. | 2004 Jun |
|
Carbonylation of glycolytic proteins is a key response to drug-induced oxidative stress and apoptosis. | 2004 Mar |
|
Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. | 2005 Feb 15 |
|
Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR). | 2005 Jul |
|
Pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for malignant ovarian germ cell tumors: report of 2 cases. | 2005 Mar-Apr |
|
Adenine nucleotides inhibit proliferation of the human lung adenocarcinoma cell line LXF-289 by activation of nuclear factor kappaB1 and mitogen-activated protein kinase pathways. | 2006 Aug |
|
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. | 2006 May 1 |
|
Signaling from p53 to NF-kappaB determines the chemotherapy responsiveness of neuroblastoma. | 2006 Nov |
|
BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. | 2007 Aug 1 |
|
Curative surgery after neoadjuvant chemotherapy in metastatic poorly differentiated neuroendocrine carcinoma. | 2007 Dec |
|
Dielectrophoretic detection of membrane morphology changes in Jurkat T-cells undergoing etoposide-induced apoptosis. | 2007 Feb |
|
Modulation of topoisomerase IIalpha expression by a DNA sequence-specific polyamide. | 2007 Jan |
|
A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). | 2007 Nov 15 |
|
In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen. | 2007 Sep 15 |
|
Glassy cell carcinoma of the uterine cervix responsive to neoadjuvant intraarterial chemotherapy. | 2008 Dec |
|
Treatment experiences of testicular cancer in Hispanic patients with Down's syndrome at the National Cancer Institute of Mexico. | 2008 Nov |
|
Haematopoietic stem cell transplantation for autoimmune disorders. | 2008 Nov |
|
Primary sinonasal choriocarcinoma. | 2009 Apr |
|
[Diabetes insipidus followed, after 4 years, with dysarthria and mild right-sided hemiparesis--the first clinical signs of Erdheim-Chester disease. Description and depiction of a case with a review of information on the disease]. | 2009 Dec |
|
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. | 2009 Oct |
|
Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. | 2010 Dec |
|
Activation of P53 in HepG2 cells as surrogate to detect mutagens and promutagens in vitro. | 2010 Oct 5 |
|
Management of non-gestational ovarian choriocarcinoma: laparoscopy can be essential. Report of two cases. | 2010 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: the recommended dose of VePesid (Etoposide) Capsules is two times the IV dose rounded to the nearest 50 mg
50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5 (testicular cancer)
35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days (small cell lung cancer)
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9116336
Apoptosis of thymocytes has been investigated by morphological, biochemical and cytometric techniques, both in non-perturbed conditions and after exposure to the topoisomerase-II inhibitor etoposide in vitro. At low (0.1 to 10 uM) etoposide concentrations apoptotic cells had cytoplasm patterns similar to naturally occurring apoptotic thymocytes, whereas at high (50 to 100 uM) concentrations extensive organelle damage took place.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:01:26 GMT 2025
by
admin
on
Mon Mar 31 18:01:26 GMT 2025
|
Record UNII |
6PLQ3CP4P3
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175609
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
||
|
NDF-RT |
N0000000176
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
||
|
WHO-VATC |
QL01CB01
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
||
|
NCI_THESAURUS |
C1331
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
||
|
LIVERTOX |
NBK548102
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
||
|
WHO-ATC |
L01CB01
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1112
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
33419-42-0
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
CHEMBL44657
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
3835
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
1268808
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
C491
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
6517
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
251-509-1
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
6PLQ3CP4P3
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
4179
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | RxNorm | ||
|
D005047
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
m5199
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000082091
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
36462
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
SUB07337MIG
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
4911
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
ETOPOSIDE
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
DTXSID5023035
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
DB00773
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
ETOPOSIDE
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | Description: A white or almost white, crystalline powder.Solubility: Practically insoluble in water; sparingly soluble in methanol R; slightly soluble in ethanol (~750 g/l) TS and dichloromethane R.Category: Cytotoxic drug.Storage: Etoposide should be kept in a tightly closed container.Labelling: The designation Etoposide for parenteral use indicates that the substance complies with the additional requirementsand may be used for parenteral administration. Expiry date.Additional information:. CAUTION - Etoposide must be handled with care, avoiding contact with the skin and inhalation of airborne particles.Requirement: Etoposide contains not less than 98.0% and not more than the equivalent of 102.0% of C29H32O13, calculated with reference to the dried substance. | ||
|
6815
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
6PLQ3CP4P3
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
141540
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY | |||
|
Etoposide
Created by
admin on Mon Mar 31 18:01:26 GMT 2025 , Edited by admin on Mon Mar 31 18:01:26 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
BINDING
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
PLASMA; URINE
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|